Freenome is understood for seeing what humans cannot see. By coding noncellular biomarker patterns of once-unthinkable quality, Freenome’s blood tests area unit hopped up by its multi-omics platform and designed to find cancer with the assistance of machine learning and biological science at its earliest stages to assist clinicians to optimize treatments and therefore the next generation of exactness therapies.
How will the Multiomics Platform Work?
By coaching on thousands of cancer-positive blood samples, Freenome’s multi-omics platform learns that biomarker patterns signify cancer’s sort and effective treatment pathways. coaching on healthy samples helps consultants to determine what a standard composition of noncellular biomarkers ought to seem like. This distinctive construct of Freenome makes the corporate stand out among all.
What will the Multiomics Platform Detect?
Freenome’s multi-omics platform detects key biological signals from a routine blood draw. The platform integrates assays for noncellular deoxyribonucleic acid, methylation, and supermolecules with advanced machine biology and machine learning techniques to grasp additive signatures for early cancer detection.
This strategy incorporates a third-dimensional read of each tumor- and non-tumor-derived (e.g. immune) signature that changes the first detection of cancer, rather than relying solely on tumor-derived markers, which can miss the first signs of cancer.
Mapping the Multiomics of Blood
Mapping of the multi-omics of blood-based on cfDNA, cfRNA, and protein.
cfDNA: This method provides insights into immunologic response and tumor heterogeneousness.
cfRNA: Reveals organic phenomenon changes within the body related to tumor formation.
Proteins: Provides a higher-order dimension to immunogenic and oncogenic signals.
By combining deep experience in biological science and advanced machine techniques like computing, machine learning, and additional to acknowledge disease-associated patterns among billions of current, noncellular biomarkers, Freenome is developing straightforward and correct blood tests for early cancer detection and integration the unjust insights into health systems to operationalize a circuit between care and science.
Follow and connect with us on Facebook, LinkedIn & Twitter
